PARIS, FRANCE., Dr. Michael Mullen, Cardiologist St. Bartholemews Hospital, London and Dr. Yuriy Pya,CEO and Chief of the National Research Center for Cardiac Surgery (NRCCS), Astana, Kazakhstan, ...
May 18, 2012 (Paris, France) — Early data from the SOURCE XT registry on high-risk patients treated with the Sapien XT (Edwards Lifesciences) transcatheter aortic valve show that this next-generation ...
Micro Interventional Devices, Inc.™ (MID), the world leader in minimally invasive and catheter-based compliant fixation technologies addressing structural heart disease announced today that it ...
Transapical access is based on decades of clinical experience with de-airing the heart, through the tip (apex) of the left ventricle, during routine cardiac surgical interventions. Insertion of a ...
Transcatheter aortic valve replacement (TAVR) by the transaortic route may result in less bleeding and fewer vascular complications than the transapical route, rendering the former technique ...
The mitral valve allows blood to flow from the left atrium to the left ventricle. Mitral valve regurgitation happens when the valve does not close properly and blood flows back into the atrium from ...
Mitral valve replacement is where an artificial prosthetic valve (bioprosthetic or mechanical) is inserted by open heart surgery. It is most commonly done for severe symptomatic mitral regurgitation ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients who underwent transcatheter valve-in-valve repair of a failed surgical mitral ...
Please provide your email address to receive an email when new articles are posted on . In high-risk patients with predominant aortic regurgitation, transapical implantation of a new self-expandable ...
The CE Mark pivotal study is ongoing, and 120 patients are planned to be enrolled. In Barcelona, Treede reported on the first 61 patients to receive the valve, although one did not receive the Engager ...
Transcatheter aortic valve implantation has evolved as a viable therapeutic option for high-risk, elderly patients with symptomatic aortic stenosis in select cardiac centers with experience of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback